Ovoca Bio (OVXA) H2 2023 earnings summary

Executive summary

• Focused on development of Orenetide, a novel treatment for HSDD, until negative Phase II trial results in July 2023 led to suspension of all R&D activities and a strategic pivot.

• Management shifted to cost control, asset disposal in complex jurisdictions, and exploration of new business opportunities.

• Significant efforts made to maintain financial stability and minimize shareholder losses while seeking new strategic directions.

Financial highlights

• Total comprehensive loss for 2023 was €5.13m / US$5.44m, improved from €5.81m / US$7.07m in 2022.

• Net loss for 2023 was €4.70m / US$5.09m (2022: €5.61m / US$5.92m).

• Cash and liquid investments at year-end were €3.34m / US$3.68m (2022: €3.70m / US$3.95m).

• No dividend recommended for 2023.

• R&D costs recognized as administrative expenses were €0.42m / US$0.46m (2022: €2.46m / US$2.59m).

• Goodwill fully impaired in 2023, resulting in a €4.24m / US$4.59m charge.

Outlook and guidance

• All Orenetide development suspended; management is investigating new strategic opportunities aligned with internal competencies.

• Low expenditure expected for 2024 due to R&D suspension; sufficient funding for administrative and advisory costs.

• Board believes current cash resources are adequate for the foreseeable future while exploring new investments.